Development of hybrid immunity during a period of high incidence of Omicron infections.
Details
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_58F5CD0974E9
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Development of hybrid immunity during a period of high incidence of Omicron infections.
Journal
International journal of epidemiology
Working group(s)
Corona Immunitas Research Group
Contributor(s)
Albanese E., Amati R., Amendola A., Anagnostopoulos A., Anker D., Annoni A.M., Aschmann H., Azman A., Bal A., Ballouz T., Baysson H., Bezani K., Blattmann A., Bleich P., Bochud M., Bodenmann P., Rumley G.B., Buttaroni P., Dettwiler A.B., Camerini A.L., Chiolero A., Chocano-Bedoya P.O., Collombet P., Corna L., Crivelli L., Cullati S., D'Acremont V., Santos DSDC, Deschamps A., D'Ippolito P., Domenghino A., Dubos R., Dumont R., Duperrex O., Dupraz J., Egger M., El-May E., El Merjani N., Engler N., Epure A.M., Erksam L., Estoppey S., Fadda M., Faivre V., Fehr J., Felappi A., Fiordelli M., Flahault A., Fornerod L., Corti C.F., Francioli N., Frangville M., Frank I., Franscella G., Frei A., Geigges M., Nusslé S.G., Graindorge C., Guessous I., Harju E., Harnal S., Imboden M., Jendly E., Jeong A., Kahlert C.R., Kaiser L., Kaufmann L., Kaufmann M., Keidel D., Kessler S., Kohler P., Krähenbühl C., Kriemler S., Lamour J., Levati S., Lescuyer P., Loizeau A., Lorthe E., Luedi C., Magnin J.L., Martinez C., Masserey E., Menges D., Michel G., Morese R., Mösli N., Noël N., Paris D.H., Pasquier J., Pennacchio F., Pfister S., Piumatti G., Poulain G., Probst-Hensch N., Pugin C., Puhan M., Pullen N., Radtke T., Rasi M., Richard A., Richard V., Robert C.F., Rodondi P.Y., Rodondi N., Sabatini S., Samir K., Zozaya J.S., Schlüter V., Schmid A., Schneider V., Schüpbach M., Schwab N., Semaani C., Speierer A., Steiner-Dubuis A., Stringhini S., Tancredi S., Testini S., Thabard J., Tonolla M., Troillet N., Ulyte A., Vassaux S., Vermes T., Villers J., von Wyl V., Wagner C., Wenger R., West E., Wisniak A., Witzig M., Zaballa M.E., Zens K., Zuppinger C.
ISSN
1464-3685 (Electronic)
ISSN-L
0300-5771
Publication state
Published
Issued date
25/12/2023
Peer-reviewed
Oui
Volume
52
Number
6
Pages
1696-1707
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
Seroprevalence and the proportion of people with neutralizing activity (functional immunity) against SARS-CoV-2 variants were high in early 2022. In this prospective, population- based, multi-region cohort study, we assessed the development of functional and hybrid immunity (induced by vaccination and infection) in the general population during this period of high incidence of infections with Omicron variants.
We randomly selected and assessed individuals aged ≥16 years from the general population in southern (n = 739) and north-eastern (n = 964) Switzerland in March 2022. We assessed them again in June/July 2022, supplemented with a random sample from western (n = 850) Switzerland. We measured SARS-CoV-2 specific IgG antibodies and SARS-CoV-2 neutralizing antibodies against three variants (ancestral strain, Delta, Omicron).
Seroprevalence remained stable from March 2022 (97.6%, n = 1894) to June/July 2022 (98.4%, n = 2553). In June/July, the percentage of individuals with neutralizing capacity against ancestral strain was 94.2%, against Delta 90.8% and against Omicron 84.9%, and 50.6% developed hybrid immunity. Individuals with hybrid immunity had highest median levels of anti-spike IgG antibodies titres [4518 World Health Organization units per millilitre (WHO U/mL)] compared with those with only vaccine- (4304 WHO U/mL) or infection- (269 WHO U/mL) induced immunity, and highest neutralization capacity against ancestral strain (hybrid: 99.8%, vaccinated: 98%, infected: 47.5%), Delta (hybrid: 99%, vaccinated: 92.2%, infected: 38.7%) and Omicron (hybrid: 96.4%, vaccinated: 79.5%, infected: 47.5%).
This first study on functional and hybrid immunity in the Swiss general population after Omicron waves showed that SARS-CoV-2 has become endemic. The high levels of antibodies and neutralization support the emerging recommendations of some countries where booster vaccinations are still strongly recommended for vulnerable persons but less so for the general population.
We randomly selected and assessed individuals aged ≥16 years from the general population in southern (n = 739) and north-eastern (n = 964) Switzerland in March 2022. We assessed them again in June/July 2022, supplemented with a random sample from western (n = 850) Switzerland. We measured SARS-CoV-2 specific IgG antibodies and SARS-CoV-2 neutralizing antibodies against three variants (ancestral strain, Delta, Omicron).
Seroprevalence remained stable from March 2022 (97.6%, n = 1894) to June/July 2022 (98.4%, n = 2553). In June/July, the percentage of individuals with neutralizing capacity against ancestral strain was 94.2%, against Delta 90.8% and against Omicron 84.9%, and 50.6% developed hybrid immunity. Individuals with hybrid immunity had highest median levels of anti-spike IgG antibodies titres [4518 World Health Organization units per millilitre (WHO U/mL)] compared with those with only vaccine- (4304 WHO U/mL) or infection- (269 WHO U/mL) induced immunity, and highest neutralization capacity against ancestral strain (hybrid: 99.8%, vaccinated: 98%, infected: 47.5%), Delta (hybrid: 99%, vaccinated: 92.2%, infected: 38.7%) and Omicron (hybrid: 96.4%, vaccinated: 79.5%, infected: 47.5%).
This first study on functional and hybrid immunity in the Swiss general population after Omicron waves showed that SARS-CoV-2 has become endemic. The high levels of antibodies and neutralization support the emerging recommendations of some countries where booster vaccinations are still strongly recommended for vulnerable persons but less so for the general population.
Keywords
Humans, Cohort Studies, Incidence, Prospective Studies, Seroepidemiologic Studies, Antibodies, Viral, Adaptive Immunity, Immunoglobulin G, Vaccination, COVID-19, SARS-CoV-2, cohort, functional immunity, hybrid immunity, infection, neutralization, population-based, seroprevalence, vaccination
Pubmed
Web of science
Open Access
Yes
Create date
07/07/2023 8:29
Last modification date
05/01/2024 8:15
Usage data
